This meeting is for New Zealand healthcare professionals involved in the management of oncology patients, specifically medical oncologists and pharmacists.
Meeting participants can expect to learn about:
1. The development of biosimilar drugs and regulatory pathway for acceptance as similar / non-inferior to the reference drug;
2. Clinical and real-life data on Trastuzumab Biosimilar Herzuma® from Celltrion Healthcare - South Korea , registered in New Zealand. The brand is currently not listed on the PHARMAC schedule. However, it is available to treat patients with private insurance and / or willing to pay for the cost of treatment as a more cost effective option.
Attendees will be eligible to receive a Certificate of Attendance for professional development records.
This meeting has been sponsored by Celltrion Healthcare New Zealand Ltd.
Any questions related to this meeting should be directed to Andreas Wortmann, MSL (firstname.lastname@example.org) or Anthony Boteju, Head of Marketing (email@example.com).